{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:51:45Z","timestamp":1790092305017,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijrobp.2023.05.025","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T20:37:04Z","timestamp":1684787824000},"page":"31-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Late Toxicity and Health-Related Quality of Life Following Definitive Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-7541","authenticated-orcid":false,"given":"Marieke","family":"Pape","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde M.","family":"Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thom M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Kuijper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline A.J.","family":"Vissers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth D.","family":"Geijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam A.G.","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob H.A.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.05.025_bib0001","doi-asserted-by":"crossref","first-page":"194","DOI":"10.6004\/jnccn.2015.0028","article-title":"Esophageal and esophagogastric junction cancers, version 1.2015","volume":"13","author":"Ajani","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0002","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0003","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0004","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (artdeco study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with folfox versus fluorouracil and cisplatin in patients with oesophageal cancer (prodige5\/accord17): Final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2021.10.013","article-title":"Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma \u2013 A systematic review and meta-analysis","volume":"165","author":"Chow","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101945","article-title":"Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis","volume":"83","author":"Marchetti","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-14-56","article-title":"Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma","volume":"14","author":"Haj Mohammad","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103069","article-title":"Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis","volume":"154","author":"van den Boorn","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/atm.2017.11.38","article-title":"Quality of life assessment in esophagectomy patients","volume":"6","author":"Alghamedi","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0011","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0012","unstructured":"Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Available at: www.training.cochrane.org\/handbook. Accessed June 15, 2023."},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0013","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2003.12.121","article-title":"Beyond the development of health-related quality-of-life (hrqol) measures: A checklist for evaluating hrqol outcomes in cancer clinical trials\u2014Does hrqol evaluation in prostate cancer research inform clinical decision making?","volume":"21","author":"Efficace","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0014","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s11136-012-0290-8","article-title":"Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative treatment for esophageal cancer","volume":"22","author":"Jacobs","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0016","first-page":"12","article-title":"Quality of life during palliative systemic therapy for esophagogastric cancer: Systematic review and meta-analysis","volume":"112","author":"van Kleef","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0017","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/bjs.5888","article-title":"Quality of life during potentially curative treatment for locally advanced oesophageal cancer","volume":"94","author":"Avery","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2017.07.038","article-title":"Health-related quality of life results from the prodige 5\/accord 17 randomised trial of folfox versus fluorouracil-cisplatin regimen in oesophageal cancer","volume":"84","author":"Bascoul-Mollevi","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0019","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10147-005-0506-9","article-title":"Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin","volume":"10","author":"Burmeister","year":"2005","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0020","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00268-010-0595-0","article-title":"Radical resection or chemoradiotherapy for cervical esophageal cancer?","volume":"34","author":"Chou","year":"2010","journal-title":"World J Surg"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.prro.2019.07.003","article-title":"A comparison of patient-reported health-related quality of life during proton versus photon chemoradiation therapy for esophageal cancer","volume":"9","author":"Garant","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0022","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.clon.2007.12.002","article-title":"Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer","volume":"20","author":"Gillham","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0023","first-page":"45","article-title":"Longitudinal quality-of-life analysis of RTOG 94-05 (INT 0123): A phase III trial of definitive chemoradiotherapy for esophageal cancer","volume":"4","author":"Kachnic","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0024","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3892\/mco.2014.313","article-title":"Quality of life in patients with esophageal cancer receiving definitive chemoradiotherapy or esophagectomy","volume":"2","author":"Lv","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/bjc.2015.258","article-title":"Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer","volume":"113","author":"Rees","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0026","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jjco\/hyt170","article-title":"Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer","volume":"44","author":"Yamashita","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0027","doi-asserted-by":"crossref","first-page":"22711","DOI":"10.18632\/oncotarget.8050","article-title":"Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: A phase II study","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0028","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)","volume":"281","author":"Cooper","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0029","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.2017.21","article-title":"Long-term results and recurrence patterns from scope-1: A phase II\/III randomised trial of definitive chemoradiotherapy +\/- cetuximab in oesophageal cancer","volume":"116","author":"Crosby","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0030","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/0284186X.2020.1753889","article-title":"A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer","volume":"59","author":"de Vos-Geelen","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0031","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/cam4.2933","article-title":"Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study","volume":"9","author":"Fan","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0032","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/dote.12146","article-title":"Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus","volume":"27","author":"Gkika","year":"2014","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0033","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/0971-5851.133722","article-title":"A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer","volume":"35","author":"Gupta","year":"2014","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0034","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5114\/jcb.2018.76843","article-title":"Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: A single institutional study","volume":"10","author":"Halder","year":"2018","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/030089161209800108","article-title":"Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasis","volume":"98","author":"Han","year":"2012","journal-title":"Tumori"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0036","first-page":"1757","article-title":"Proton beam therapy combined with concurrent chemotherapy for esophageal cancer","volume":"35","author":"Ishikawa","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0037","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1200\/JCO.2003.03.055","article-title":"Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus","volume":"21","author":"Ishikura","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0038","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/jrr\/rrw078","article-title":"Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method","volume":"58","author":"Ito","year":"2017","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0039","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","article-title":"Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906)","volume":"81","author":"Kato","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0040","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jgo.2019.08.009","article-title":"Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer","volume":"11","author":"Kawamoto","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0041","first-page":"31","article-title":"Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (ldfp) for stage I-II esophageal carcinoma","author":"Kumabe","year":"2018","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0042","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3892\/ol.2011.287","article-title":"Comparison between late-course accelerated hyperfractionation radiotherapy and concurrent chemoradiotherapy in patients with esophageal carcinoma","volume":"2","author":"Lin","year":"2011","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0043","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1245\/s10434-019-07264-4","article-title":"Concurrent selective lymph node radiotherapy and s-1 plus cisplatin for esophageal squamous cell carcinoma: A phase II study","volume":"26","author":"Liu","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0044","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"Int 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2008.10.075","article-title":"Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma","volume":"75","author":"Morota","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0046","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/jjco\/hys112","article-title":"Long-term follow-up of a randomized phase II study of cisplatin\/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101\/JROSG021)","volume":"42","author":"Nishimura","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0047","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/1471-2407-9-408","article-title":"Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma","volume":"9","author":"Osawa","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0048","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1748-717X-9-191","article-title":"Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer","volume":"9","author":"Roeder","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0049","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10147-006-0617-y","article-title":"Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP)","volume":"12","author":"Sasamoto","year":"2007","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0050","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/cam4.897","article-title":"Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: A prospective phase II trial","volume":"5","author":"Song","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0051","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00000421-200006000-00004","article-title":"Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus","volume":"23","author":"Stuschke","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0052","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000012015","article-title":"Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the cervical oesophagus","volume":"57","author":"Stuschke","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0053","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jjco\/hyu047","article-title":"High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer","volume":"44","author":"Suh","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0054","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.7150\/jca.23456","article-title":"Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil improves survival of patients with advanced esophageal cancer compared with conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil","volume":"9","author":"Tamaki","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dow033","article-title":"Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer","volume":"30","author":"van Ruler","year":"2017","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0056","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/jtd.2017.03.105","article-title":"Definitive concurrent chemoradiotherapy with s-1 and cisplatin in elderly esophageal squamous cell carcinoma patients","volume":"9","author":"Wang","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0057","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13014-015-0482-9","article-title":"Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: A single institutional retrospective study","volume":"10","author":"Yamashita","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0058","series-title":"Eortc qlq-c30 reference values","author":"Scott","year":"2008"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0059","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/01.JTO.0000437420.38972.fb","article-title":"Esophageal cancer recurrence patterns and implications for surveillance","volume":"8","author":"Lou","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ijc.34488","article-title":"Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: A population-based study","volume":"153","author":"Kuijper","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0061","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fonc.2019.00877","article-title":"Radiation-induced lung injury (RILI)","volume":"9","author":"Giuranno","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0062","first-page":"1","article-title":"Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: A systemic review and pooled analysis of the literature","volume":"30","author":"Du","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0063","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1586\/14737140.2015.1074041","article-title":"High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: A systematic review and pooled analysis","volume":"15","author":"Song","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0064","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00432-022-03932-3","article-title":"Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world","volume":"148","author":"Kaku","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0065","article-title":"Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: A randomized clinical trial","volume":"5","author":"Ai","year":"2022","journal-title":"J Am Med Assoc Netw Open"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0066","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: The consort pro extension","volume":"309","author":"Calvert","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0067","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2020.7631","article-title":"Source: Prediction models for overall survival in patients with metastatic and potentially curable esophageal and gastric cancer","volume":"19","author":"van den Boorn","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0068","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.coc.0000162443.08446.00","article-title":"Intensity-modulated radiation therapy in head and neck cancers: Dosimetric advantages and update of clinical results","volume":"28","author":"Puri","year":"2005","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.ijrobp.2023.05.025_bib0069","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.oraloncology.2018.11.015","article-title":"Intensity modulated proton therapy (IMPT) \u2013 The future of imrt for head and neck cancer","volume":"88","author":"Moreno","year":"2019","journal-title":"Oral Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623005126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623005126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:07:25Z","timestamp":1759745245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623005126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0360301623005126"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.025","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late Toxicity and Health-Related Quality of Life Following Definitive Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}